Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
176 participants
INTERVENTIONAL
2001-06-30
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
bronchoscopy
2 bronchoscopies 4 hours apart; The first to instill the 3 experimental biologic agents in separate airways (HDM, LPS and saline-placebo), the second to perform BAL and brush biopsies 4 hours later in the same airways.
LPS endotoxin, saline, HDM
instillation of interventional products during bronchoscopy each down a different airway, each subject acts as their own control.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LPS endotoxin, saline, HDM
instillation of interventional products during bronchoscopy each down a different airway, each subject acts as their own control.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Asthma subjects will be required to have either mild or moderate persistent asthma; positive methacholine challenge
* Atopic subjects should have seasonal allergy symptoms requiring medication and have positive skin test to house dust mite and at least 3 additional allergens. Serum IgE level \>100.
* Willing/able to give informed consent \& adhere to visit/protocol schedules.
* Screening visit laboratory, C-Xray, EKG, results within normal limits
* Women of childbearing potential must have a negative serum pregnancy test
* Screening Pulmonary Function testing above study criteria parameters
Exclusion Criteria
* Antibiotic administration within the previous 30 days.
* Viral respiratory infection within the previous 14 days.
* History of severe asthma requiring intubation.
* Occupational exposure to hay or grain dust.
* Significant exposure history to cigarette smoke
* Past or present history of allergen immunotherapy
* Underlying illnesses that may result in altered lung function
* Students or employees under direct supervision by protocol investigators are ineligible
* Subjects allergic to medications used (or potentially used) in the study will be excluded.
* Subjects using aspirin will be excluded
* Subjects who abuse alcohol or illicit substances will be excluded
* Medication use other than for asthma, allergies or contraception
* Other medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
* Nursing mothers
* Other investigational medication within the last 30 days
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Center for Research Resources (NCRR)
NIH
National Institute of Environmental Health Sciences (NIEHS)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Duke University Medical Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sundy S. Sundy, MD. PhD.
Role: PRINCIPAL_INVESTIGATOR
Duke University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Duke University Medical Center
Durham, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2357
Identifier Type: -
Identifier Source: secondary_id
NCRR-M01RR00030-0183
Identifier Type: -
Identifier Source: org_study_id